Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CKLIFE SCIENCES Resumes Trading of Shrs, Once Leapfrogs 42% on Cancer Vaccine Patent Applications Filed in HK/ US
Recommend 22 Positive 50 Negative 15 |
||||
|
||||
|
CKLIFE SCIENCES (00775.HK) resumed trading of its shares today (11th), and once leapfrogged as high as nearly 42% to a high of $0.68. The stock last printed at $0.61, up 27.08%, with 16.627 million shares traded, involving $10.8023 million. CKLIFE SCIENCES obtained promising early results in laboratory tests of its preclinical stage novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), as announced by CKLIFE SCIENCES. The Company has filed an Original Grant Patent application with the Intellectual Property Department of Hong Kong and a provisional patent application with the US Patent and Trademark Office for its circRNA and fusion protein TROP2 cancer vaccines. After a thorough assessment, the Company concluded that the successful commercialization of this TROP2 cancer vaccine could potentially generate significant economic benefits for the Company. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
